挑战"不可抗药" - - 准STAT3,但发现有力的TrkA向抑制剂
Petar Iliev1, Conall McCutcheon1, Tizita H Admas1
1Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver V6T 1Z3, Canada.
Journal of medicinal chemistry
|April 17, 2025
概括
研究人员开发了一种新的药物发现方法,专注于目标参与. 这种方法确定了热胺受体激酶A (TrkA) 的新兴抑制剂,这是一个有前途的癌症标,导致化合物PI-15.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 信号转换器和转录3激活器 (STAT3) 是一个具有挑战性的抗癌点,原因是复杂的信号和药物治疗能力差.
- 开发有效的STAT3抑制剂需要创新的查和优化策略.
- 目标参与对于在发现管道的早期验证候选药物至关重要.
研究的目的:
- 为发现新型STAT3抑制剂建立一个以目标参与为重点的查和优化管道.
- 为了识别和表征具有高亲和力和TrkA选择性的化合物,一个相关的激酶.
- 在细胞癌症模型中证明已确定抑制剂的疗效.
主要方法:
- 差分扫描度 (DSF) 高通量选用于识别STAT3稳定剂.
- 细胞热转移测试 (CETSA) 用于目标参与验证.
- 坐标的生化和细胞测试以评估TrkA.的抑制器亲和力和选择性.
- 在体外和细胞测试以评估癌症模型中的化合物疗效.
主要成果:
- 最初的查确定了稳定STAT3的化合物,但也显示出对TrkA的高度亲和力.
- 优化改进了对TrkA的抑制剂选择性,导致强大的TrkA抑制.
- 化合物PI-15在细胞测试中显示出强大的目标参与和TrkA抑制.
- PI-15在细胞TrkA癌症模型中显示出有效性.
结论:
- 一种以目标参与为中心的方法对于早期药物发现至关重要,特别是对于像STAT3.3这样具有挑战性的目标.
- 该管道成功识别了PI-15,这是一个强大的TrkA抑制剂,具有证明的细胞疗效.
- 优先考虑严格的目标参与验证,加速发现癌症治疗有前途的候选药物.
更多相关视频
07:12Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
3.4K
10:22Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis
Published on: August 15, 2013
30.4K
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K